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Abstract Biosimilar drugs are highly similar to an originator
(reference) biologic, with no clinically meaningful differences
in terms of safety or efficacy. As biosimilars offer the potential
for lower acquisition costs versus the originator biologic,
evaluating the economic implications of the introduction of
biosimilars is of interest. Budget impact analysis (BIA) is a
commonly used methodology. This review of published BIAs
of biosimilar fusion proteins and/or monoclonal antibodies
identified 12 unique publications (three full papers and nine
congress posters). When evaluated alongside professional
guidance on conducting BIA, the majority of BIAs identified
were generally in line with international recommendations.
However, a lack of peer-reviewed journal articles and consid-
erable shortcomings in the publications were identified. Defi-
ciencies included a limited range of cost parameters, a reliance
on assumptions for parameters such as uptake and drug pricing,
a lack of expert validation, and a limited range of sensitivity
analyses that were based on arbitrary ranges. The rationale for
the methods employed, limitations of the BIA approach, and
instructions for local adaptation often were inadequately dis-
cussed. To understand fully the potential economic impact and
value of biosimilars, the impact of biosimilar supply, manu-
facturer-provided supporting services, and price competition
should be included in BIAs. Alternative approaches, such as
cost minimization, which requires evidence demonstrating
similarity to the originator biologic, and those that integrate a
range of economic assessment methods, are needed to assess
the value of biosimilars.
Key Points for Decision Makers
For biosimilars, there is a paucity of robust, peer-
reviewed publications of budget impact analyses
(BIAs), a common tool in reimbursement decision-
making.
Comprehensive BIAs based on robust evidence are
needed to evaluate the affordability of biosimilars,
while other types of economic evaluation are needed
to assess the value of biosimilars.
1 Introduction
Biologic drugs, also known as biopharmaceuticals or bio-
logical therapies, are genetically engineered proteins pro-
duced in living organisms such as bacteria, yeast, or human
cell lines. Unlike generic small-molecule pharmaceuticals,
which are identical to their originator, it is not possible for
a different manufacturer to produce an identical copy of an
originator biologic (also known as the ‘reference’ product)
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due to their large size, complex structure, and manufacture
in a unique line of living cells [1]. Instead, a biologic
deemed highly similar to a reference biologic is called a
‘biosimilar’.
In the USA, a biosimilar is defined as having ‘‘no
clinically meaningful differences between the biosimilar
product and the reference biologic in terms of safety, purity
and potency’’ [2, 3]. Manufacturers are required to provide
supporting evidence that it meets the standards for
biosimilarity recommended by the World Health Organi-
zation (WHO) [4] when seeking marketing approval from
the US Food and Drug Administration (FDA) [5], Euro-
pean Medicines Agency (EMA) [6], or other national
regulatory agencies. In contrast, ‘intended copies’ are
copies of originator biologics that have not undergone
rigorous comparative similarity evaluations in accordance
with WHO recommendations, but are being commercial-
ized in some countries outside Europe, the USA, or
Canada. The weight of evidence available to support
biosimilars is significantly greater than that for intended
copies, as reported in a 2016 systematic literature review
[7].
The first available biosimilars in Europe were human
growth hormones, erythropoiesis-stimulating agents, and
granulocyte-colony stimulating factors [8]. The first mon-
oclonal antibody biosimilar was approved in 2013 for
infliximab. With loss of exclusivity of a number of mon-
oclonal antibodies and fusion proteins used in immunology
and oncology occurring between 2015 and 2019, many new
biosimilars are in development or recently available
[9, 10], presenting decision-makers with an increasing
number of biologic treatment options.
Experience from European markets, where biosimilar
products were first introduced and have been available
since 2006, has shown that many of these molecules are
priced 10–30% lower than the originator biologic [8],
although cost savings with monoclonal antibodies and
fusion protein biosimilars have not been realized in all
markets [9, 10]. Despite biosimilar availability in the USA
lagging behind that in Europe, the US market for biosim-
ilars is potentially the largest in the world. Biosimilars, and
specifically the economic impact of these alterative drug
options, are now entering into formulary decisions for US
payers, as has been the case outside of the USA for over a
decade. The expectation of achieving potentially signifi-
cant health system cost savings stemming from competi-
tion among an increasing number of available biosimilars
[9, 10] has led to widespread interest in developing mod-
eling techniques that can accurately estimate the economic
impact of biosimilar adoption.
Budget impact analysis (BIA) is one technique often
used to complement other forms of economic evaluation.
While some methods of economic evaluation consider the
efficiency of healthcare resource allocation, BIA considers
its affordability [11]. Since the 1990s, many countries have
incorporated BIA into formulary listing or reimbursement
decision-making [12].
In its recent good practice guidance, the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) described the benefits and uses of BIA: ‘‘BIA
addresses the expected changes in the expenditure of a
health care system after the adoption of a new interven-
tion…. A BIA can also be used for budget or resource
planning. A BIA can be freestanding or part of a compre-
hensive economic assessment along with a CEA [cost-ef-
fectiveness analysis]’’ [12].
The main objective of a BIA is to assess the short-term
(e.g., up to 3 years, with annual estimates), undiscounted
financial consequences of the introduction of a new tech-
nology in a specific setting and from a specific payer per-
spective, taking into account healthcare resource trade-offs
and future uncertainty [13]. BIAs may be conducted by
pharmaceutical companies, independent academic groups,
or by payers.
To assess the affordability of health technologies, such
as biosimilars, payers use BIAs to support decision-making
at national, regional, and local levels. Moreover, reim-
bursement authorities increasingly require these models as
part of a formulary listing request or reimbursement sub-
mission. The importance of BIAs in decision-making var-
ies by country and by stakeholder [14]. Despite their
growing importance in healthcare decision-making, BIAs
have not been widely published in the literature. A sys-
tematic review, published in 2014, reviewed BIAs of drugs
in European Union settings published in English since 2008
[13]. The analysis found that few BIAs had been published
and many, in the opinion of the authors, were of poor
quality, relying on weak data sources. However, subse-
quent to that review, ISPOR published updated guidelines
on BIAs [12], which may have positively affected the
quality of BIAs conducted since the ISPOR guidelines
were published.
Given the challenges of assessing the budget impact in
the context of overall evaluation of biosimilars, this review
examines the currently available published literature on
BIAs for biosimilars of fusion proteins and monoclonal
antibodies in chronic inflammatory disease and oncology.
With the increasing number of newly approved biologic
drugs in these therapeutic areas, decision-makers in mul-
tiple markets are presented with a growing number of
agents to consider in formulary and reimbursement
assessments. As BIAs focus on affordability rather than
‘value’, they are just one tool among several for assessing
the overall value for money that budget holders consider as
they contend with access policies for a range of competing
conditions, each with multiple treatment options, among a
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diverse population. This analysis focuses on budget impact
and primarily affordability, but it acknowledges that the
value offered by new technologies such as biosimilars goes
beyond budget affordability over a given time horizon.
In this review we:
• assess whether the identified models are ‘fit for
purpose’; i.e., in line with published guidelines for
conducting BIAs and of sufficient utility to meet the
needs of decision-makers;
• provide recommendations to improve budget impact
modeling and reporting in future BIA publications for
biosimilars, to address typical payer and provider
considerations; and,
• introduce broader issues, concepts, and value assess-
ment techniques that should be considered when
moving beyond short-term affordability, to fully assess
the true economic value of biosimilars.
2 Methods
Searches of published literature were conducted without
date limitation in MEDLINE/MEDLINE In-Process and
EMBASE on 30 June 2016. Searches included terms to
capture fusion proteins and/or monoclonal antibodies,
biosimilars, and BIAs. One reviewer evaluated titles and
abstracts to identify English-language BIAs. A second
reviewer was consulted when eligibility was unclear. In
addition, ISPOR conference abstracts were hand-searched
to identify relevant BIA publications.
In the absence of a formal ‘gold-standard’ checklist for
evaluating the quality of BIAs, elements of the ISPOR
good practice guidelines [12] were used to guide evalua-
tion. A detailed list of factors for consideration in design-
ing and evaluated BIAs, adapted from the ISPOR report, is
provided in Table 1. Based on these recommendations, the
following subset of criteria was used to assess BIA in this
study: intervention, indication, country, time horizon, costs
included (e.g., drug only vs. in addition to administration,
monitoring, treatment-related adverse events, and savings
from avoided healthcare utilization), uptake and price
parameters, and assumptions and scenario analyses.
3 Results
3.1 Review of the Published Literature
After initial screening, 16 publications reporting BIAs for
biosimilar fusion proteins and/or monoclonal antibodies
were identified, including three full papers and 13 congress
abstracts. However, one full paper [16] had a title similar to
a congress abstract published earlier by the same authors
[17]. Similarly, a full paper by Jha et al. [18] reported an
analysis similar to two earlier congress abstracts [19, 20].
In the current review, the full papers were selected for
inclusion in the analysis over the preceding abstracts,
which were omitted from the analysis to avoid duplication.
An additional published BIA of an infliximab biosimilar
was identified [21]; however, as it was published in Italian
and the English-language abstract provided insufficient
information for evaluation, it was excluded from this
review. The remaining publications comprised three full
papers plus nine abstracts presented as posters at confer-
ences (all but one poster was obtained), for a total of 12
included publications. Characteristics of the included
publications are summarized in Table 2. Table 3 reports
the uptake and pricing parameters, including those to which
the results were reported to be sensitive.
In six of the 12 included publications, at least one other
publication was identified that had a common author(s),
intervention, set of assumption, time horizon, and/or set-
ting. These were deemed to be different versions of the
same or similar core model, adapted for different countries
and treatment settings. For example:
• Brodszky et al. [16] stated that their BIA is an
adaptation of the model in the earlier publication by
Brodszky et al. [15].
• Kim et al. [22] and Kim et al. [23] had the same pricing
assumptions, time horizon (5 years), and market uptake
assumptions.
• Two 2015 publications by Ruff et al. appeared to be the
same or very similar models of an etanercept biosim-
ilar: one on rheumatoid arthritis [24] and one on
rheumatoid arthritis, psoriatic arthritis, psoriasis, and
ankylosing spondylitis indications [25] for etanercept
treatment in adults.
The literature searches identified two other review arti-
cles on BIAs, both focused on rheumatology, which were
used to identify some of the BIA publications included in
this review. Faleiros et al. [26] identified eight publications
[15, 18, 22, 24, 25, 27–29] and Gulacsi et al. [29] identified
three publications [15, 22, 27] in this review.
3.2 Are Current Published Budget Impact Models
of Biosimilars Fit for Purpose?
A striking discovery of the current review was the apparent
paucity of published data on BIAs for biosimilars. Only
three full peer-reviewed papers were identified that pre-
sented budget impact models for biosimilar fusion proteins
and/or monoclonal antibodies. Table 4 summarizes the
three papers according to recommendations derived from
the ISPOR 2014 guidelines [12]. A full assessment of the
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models presented in poster format was limited by the level
of information available in each poster (all but one poster,
which was authored by Kim et al. [23], were available and
reviewed). Observations from these assessments have been
included in the discussion, where relevant.
3.2.1 Purpose and Perspective
The full papers by Brodszky et al. [15, 16] specified the
setting, perspective (third-party payer), and patient
population eligibility criteria in their evaluation of the
budget impact of the biosimilar infliximab in six Eastern
European countries, across several disease areas, from a
third-party payer perspective (Table 2). Although not
explicitly stated in Jha et al. [18], it can be inferred based
on the text that the European country-level budget impact
models presented were from a third-party payer perspec-
tive. Among the posters, BIAs were conducted from
combined payer and patient perspectives in two studies by
the same lead author [22, 23], from a payer perspective
Table 1 Factors for consideration in the evaluation of budget impact analyses [12]
Factor Examples
Scope of the analysis
Perspective Entire health system, regional/local health system, employer, service provider (e.g., hospital or
pharmacy benefits manager), patient/household
Healthcare system Single vs. multiple payer, universal or sub-segment coverage, healthcare coverage policy (e.g.,
30-day hospital readmission), health technology access/reimbursement restrictions, patient co-pay
requirements
Indications and population Included groups, both by disease area/indication and by sub-population
Interventions Included treatments and comparators, including standard of care (including no existing treatment),
number of branded and unbranded technologies currently available or anticipated during time
horizon, treatment mix
Model assumptions and data inputs
Healthcare system population Size, demographic composition, co-morbidities, severity, new vs. existing patients, expected length
of time covered by payer, other sources of insurance (reflecting entire population for health plan)
Population eligible for intervention Disease prevalence and incidence, naı¨ve vs. treated patients, access restrictions (e.g., demographic,
co-morbidities, biomarker, disease severity/stage or previous/concurrent treatment requirements),
potential for use in ineligible populations
Technology uptake Variation by specialty, country, region (state/province; urban/non-urban), health plan/payer type,
mix of new and existing technology uptake, line of therapy, diagnostic requirements, availability
of new interventions and impact on utilization patterns (e.g., substitution or in combination of
standard of care or first treatment when only supportive care has been available), tolerability,
adherence, persistence, resistance, off-label use (since no data, recommend excluding from budget
impact analyses)
Estimated costs for modeled
intervention mix
Acquisition costs, manufacturer rebates/incentives, disease- and adverse event treatment-related
costs, payer vs. patient out-of-pocket costs; multiplied by eligible population
Model design
Time horizon 1 year common with US commercial payers; 3–5 years more likely to reflect avoided resource
utilization and events and entry of new agents; C0 years captures long-term savings and additional
entry of new agents; influence of model inputs and assumption will change with time horizon
Assumptions and methods to handle
structural uncertainty
Use of simple linear rates vs. complex non-linear functions to reflect changes over time and among
population subgroups or intervention types
Time dependencies and discounting Changes in value of currency in model, uptake of evaluated intervention, timing and uptake of new
technologies, price changes from competition and loss of exclusivity, provider and patient
perceptions of disease and interventions, covered indications, treatment practices, discounting
(recommended that none be applied in budget impact analyses)
Computing framework Simple spreadsheet with cost calculator (recommended) vs. more complex simulation models
Validation Face validity to include payer preferences for model assumptions and data inputs including source
data, verification of all formulas used in cost calculator or simulation model, comparison of
observed health plan costs with first-year budget impact estimates
Uncertainty and reporting Scenario analyses to assess plausible alternate parameter and structural assumptions, transparency of
assumptions, discussion of limitations
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Table 2 Characteristics of identified publications of budget impact analyses of biosimilar fusion proteins and monoclonal antibodies
Study Intervention Indication Country Time
horizon
(years)
Perspective and costs
Full publications
Brodszky
et al. 2014
[15]
Biosimilar
infliximab
RA Bulgaria, Czech Republic,
Hungary, Poland,
Romania, Slovakia
3 Payer (third-party) perspective
Drug costs
Administration costs
Monitoring costs
Brodszky
et al. 2016
[16]
Biosimilar
infliximab
CD Bulgaria, Czech Republic,
Hungary, Poland,
Romania, Slovakia
3 Payer (third-party) perspective
Drug costs
Administration costs
Monitoring costs
Jha et al.
2015 [18]
Biosimilar
infliximab
RA, AS, CD,
UC, PsA,
psoriasis
Belgium, Germany, Italy,
Netherlands, UK
1 Not stated; country-level budget impact perspective
(third-party payer assumed)
Drug costs
All other costs (administration. monitoring, adverse
events); assumed to be the same for biosimilar
and reference infliximab
Posters
Bocquet
et al. 2015
[30]
Infliximab
biosimilar
RA, GI,
dermatology,
other
Public hospitals in Paris,
France
1 and 3 Payer (Assistance Publique-Hoˆpitaux de Paris;
public hospital system) perspective
Hospital drug cost
Kim et al.
2014 [22]
Infliximab
biosimilar
RA France, Germany, Italy,
UK
5 Payer and patient perspectives (no further details
given)
Drug costs
Kim et al.
2015 [23]
Infliximab
biosimilar
CT-P13
CD France, Italy, UK 5 Payer and patient perspectives (no further details
given)
Drug costs
McCarthy
et al. 2013
[27]
Infliximab
biosimilar
CT-P13
RA Ireland 5 Not stated; country-level budget impact perspective
(third-party payer) assumed
Drug cost
Administration cost
Monitoring cost
Povero and
Pradelli
2015 [31]
Infliximab
biosimilar
Psoriasis Italy 3 Payer (sistema sanitario nazionale [national health
service]) perspective
Drug cost
Ruff et al.
2015 [24]
Etanercept
biosimilar
RA France, Germany, Italy,
Spain, UK
5 Payer perspective
Drug, administration, monitoring costs
Ruff et al.
2015 [25]
Etanercept
biosimilar
RA, PsA,
psoriasis, AS
France, Germany, Italy,
Spain, UK
5 Payer perspective
Drug, administration, monitoring costs
Shah and
Mwamburi
2016 [32]
Infliximab
biosimilar
Adalimumab
biosimilar
RA USA 1 Not stated; payer and patient perspectives assumed
Annual healthcare costs
Drug and administration costs
Whitehouse
et al. 2013
[28]
Infliximab
biosimilar
Adalimumab
biosimilar
Etanercept
biosimilar
RA France, Germany, UK 1 Not stated; payer and patient perspectives assumed
Drug costs
AS Ankylosing spondylitis, CD Crohn’s disease, GI gastroenterology, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
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Table 3 Summary of uptake, price parameters, and scenario analyses used in identified publications on budget impact analyses of biosimilars
Study Uptake parameters Price parameters Scenario analyses
Full publications
Brodszky
et al. 2014
[15]
Initial population treated with biologics taken from
2013 data
Scenarios (assumptions):
Only pts starting new biologic therapy can receive
biosimilar
80% of pts on originator infliximab are
interchanged to biosimilar, plus pts starting new
biologic therapy can receive biosimilar
Assumptions:
10% annual growth rate in biologics market
Biosimilar infliximab used in 65%/25% (at end of
first year) of pts for whom originator infliximab/
non-infliximab TNFi would have been selected as
first- or second-line drug
New pts receiving biologics exactly compensated
for pts leaving the model
Assumption: biosimilar price is 75% of originator
(i.e., 25% discount), based on retail prices,
derived from official national price list in each
country
Initial population
treated with
biologics
Acquisition cost of
biosimilar
infliximab
Population growth,
discontinuation,
and interchanging
rates
Brodszky
et al. 2016
[16]
Initial population treated with biologics taken from
2013 data
Scenarios (assumptions):
Only pts starting new biologic therapy can receive
biosimilar
80% of pts on originator infliximab are interchanged
to biosimilar, plus pts starting new biologic
therapy can receive biosimilar
Assumptions:
10% annual growth rate in biologics market
Biosimilar infliximab used in 75%/25% (at end of
first year) of pts for whom originator infliximab/
adalimumab would have been selected as first- or
second-line drug
New pts receiving biologics exactly compensated
for pts leaving the model
Assumption: price of biosimilar is 75% of price
of originator in all 6 countries
Number of the initial
population treated
with biologics
Acquisition cost of
biosimilar
infliximab
Population growth,
discontinuation and
interchanging rates
Jha et al.
2015 [18]
Number of pts eligible for infliximab under current
prescribing practices based on disease prevalence
and/or incidence rate in each country, grouped by
pts currently treated with originator infliximab
based on market data vs. infliximab-naive pts
Assumptions:
25% of pts on originator infliximab switch to
biosimilar infliximab
50% of infliximab-naive pts receive biosimilar
infliximab
Assumption: price of biosimilar infliximab is
discounted 10, 20, or 30% relative to originator
Biosimilar price
Number of pts
treated, prevalence
estimates, incidence
Estimates, pts’
weight
Posters
Bocquet
et al. 2015
[30]
Scenarios 1 and 2: tender between branded and
biosimilar infliximab to list only one infliximab in
hospital drug formulary
Scenario 3: tender between branded and biosimilar
infliximab for infliximab-naive pts only, with 10%
of infliximab-naive pts treated with biosimilar
infliximab if it wins the tender
Scenario 1: biosimilar price 20% discount
Scenario 2: biosimilar price 30% discount
Scenario 3: biosimilar price 20% discount
Results depend on
scenario
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(specifics not provided) in two posters by the same lead
author [24, 25], as well as from a public hospital system
[30] and a national health service [31] perspective. Per-
spective was not explicity stated in the remaining three
posters but, based on content, was assumed to be third-
party payer [27, 28, 32] (Table 2). The purpose, intended
interpretation, and target audience for the BIAs included in
this review were less clear.
3.2.2 Range of Included Costs
The reviewed publications included a limited range of
costs, including drug, administration, and monitoring costs
[15, 16, 24, 25, 27], and drug costs only [18, 22, 23,
28, 30]. Povero and Pradelli [31] included costs associated
with adverse events; Shah and Mwamburi [32] calculated
cost per effectively treated patient by dividing total annual
Table 3 continued
Study Uptake parameters Price parameters Scenario analyses
Kim et al.
2014 [22]
Number of pts eligible for infliximab based on total
population, annual population growth rate, and
disease prevalence rates in each country
Assumptions:
Biosimilar has 25% market share in year 1
Biosimilar market share growth of 20, 30, or 40%
per year
Assumption:
Price is discounted 10, 20, or 30% relative to
originator
Price and market
uptake scenarios
Kim et al.
2015 [23]
Number of pts eligible for infliximab based on total
population, annual population growth rate, and
disease prevalence rates in each country
Assumptions:
Biosimilar has 25% market share in year 1
Biosimilar market share growth of 20, 30, or 40%
per year
Assumption:
Price is discounted 10, 20, or 30% relative to
originator
Price and market
uptake scenarios
McCarthy
et al. 2013
[27]
Number of pts eligible for infliximab based on
national population, disease prevalence/incidence
rate, proportion of pts eligible for treatment with a
biologic, and proportion receiving treatment with
a biologic
Assumptions:
Annual growth rate 1.1%
Maximum conversion of all existing and new
infliximab pts to biosimilar infliximab in years
1–5 (‘maximum conversion’ not defined)
Assumption:
Price is discounted 20% relative to originator
Conversion rates
Ruff et al.
2015 [24]
Pts naive to biologics, on stable treatment, and
failing first biologic
Assumption:
Uptake from etanercept to the biosimilar of 5–40%
(2016–2020)
Assumptions:
Anti-TNF price erosion 5% per year
Biosimilar price is 10% or 25% discount
Market uptake rates
Discount to
etanercept
Ruff et al.
2015 [25]
Pts naive to biologics, stable on or failing first
biologic
Assumption:
Uptake from etanercept to the biosimilar of 5–40%
Assumptions:
Anti-TNF price erosion 5% per year
Biosimilar price is 10% or 25% discount
Market uptake rates
Discount to
etanercept
Povero and
Pradelli
2015 [31]
Total substitution of infliximab with its biosimilars Not stated Not stated
Shah and
Mwamburi
2016 [32]
Assumption:
Biosimilar market share 30% of reference biologic
Assumption:
25% cost discount
Cost discount
Market share
Whitehouse
et al. 2013
[28]
Assumption:
50% of eligible pts
Assumption:
30% cost discount
Not stated
pts Patients, TNF tumor necrosis factor, TNFi tumor necrosis factor inhibitor
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis 1053
Table 4 Full publications of budget impact models of biosimilars considered in relation to key aspects derived from the International Society for
Pharmacoeconomics and Outcomes Research guidelines on budget impact assessments [12]
Brodszky et al. 2014 [15] Brodszky et al. 2016 [16] Jha et al. 2015 [18]
Scope of the analysis
Features of the
healthcare
system
Difference in total direct costsa
The number of additional new pts who
could be treated due to cost savings
achieved
Difference in total direct costsa
The number of additional new pts who
could be treated due to cost savings
achieved
Difference in total drug costsa
The number of new pts who could be
treated due to cost savings achieved
Perspective Third-party payerb Third-party payerb Not specified: only drug costs
considereda
Eligible
population
Scenario 1: only pts starting new
biologic therapya
Scenario 2: 80% of pts receiving
originator infliximab are
interchanged to biosimilar, plus pts
starting new biological therapy
Scenario 1: only pts starting new
biologic therapya
Scenario 2: 80% of pts receiving
originator infliximab are interchanged
to biosimilar, plus pts starting new
biologic therapy
Infliximab-naı¨ve and switch pts, those
already receiving originator
infliximab were considereda
Model design
Current
intervention
Current intervention mix (including
multiple biologics) taken from real-
world 2013 market penetration data
in each countryb
Current intervention mix (including
originator infliximab and
adalimumab) taken from real-world
2013 market penetration data in each
countryb
Data on prevalence, incidence, and %
drug-treated taken from the literature
with IMS health data used to calculate
number of pts on infliximaba
Uptake of new
intervention and
market effects
Included: substitution, combination,
and expansionb
Included: substitution, combination,
and expansionb
Included: substitution, combination,
and expansionb
Off-label use of
new intervention
Not includedb Not includedb Not includedb
Cost of current
and new
intervention mix
Included: costs of drugs,
administration, and treatment
monitoring multiplied by eligible
populationb
Included: costs of drugs,
administration, and treatment
monitoring multiplied by eligible
populationb
Included: model multiplied estimated
cost per pt, based on dose, for each of
the conditions and multiplied it by
estimated eligible populationb
Condition-
related costs
Not includedc Not includedc Not includedc
Indirect costs Not includedb Not includedb Not includedb
Time horizon 3 yearsb 3 yearsb 1 yearb
Choice of
analytical
computing
framework
Not stateda Not stateda Excel-based modelb
Uncertainty and
scenario
analyses
Scenarios of different price, uptake
assumptions, and other parametersa
Scenarios of different price, uptake
assumptions, and other parametersa
Partially included: scenarios of
different price and population
estimates and other parametersa
Validation Validation not reportedc Validation not reportedc Validation not reportedc
Inputs and data sources
Size and
characteristics
of eligible
population
Partially included: population size set
on basis of real-world 2013
penetration dataa
Uptake and switching were based on
assumptionsa
Partially included: population size set
on basis of real-world 2013
penetration dataa
Uptake and switching were based on
assumptionsa
Partially included: prevalence and
incidence data taken from the
published literaturea
Assumptions were made where data
was not availablea
Intervention mix
with and without
the new
intervention
Mix of real-world data and
assumptions useda
Budget-holder data not useda
Mix of real-world data and assumptions
useda
Budget-holder data not useda
Mix of real-world data and assumptions
useda
Budget-holder data not useda
Cost of current
and new
intervention mix
Costs based on national price lists and
assumptionsa
Budget-holder data not useda
Costs based on national price lists and
assumptionsa
Budget-holder data not useda
Costs based on national price lists and
assumptionsa
Budget-holder data not useda
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costs by the number of patients defined as effectively
treated, using administrative claims data. Jha et al. [18]
acknowledged the limitation of the assumption of equiva-
lent administration and monitoring costs for biosimilar and
originator infliximab. Brodszky et al. [15, 16] acknowl-
edged the limitation of excluding societal costs. Although
drug, administration, and monitoring costs may have been
those of most interest to a third-party payer, consideration
of other cost parameters, such as cost to the patient or
societal cost offsets, would have allowed a wider applica-
tion of the analysis.
3.2.3 Time Horizon
The time horizons of the included studies ranged from 1 to
3 years [15, 16, 18, 28, 30–32], with some of the posters
reporting up to 5 years [22–25, 27]. The appropriate time
horizon depends on the intended use and audience for the
BIA; for example, a timeframe of 1 year may be relevant to
US commercial payers to correspond with health plan
enrollment and annual budget planning, although this time
period would likely not capture longer-term benefits of
treatment with biologics. However, the rationale for and
limitations of the chosen time horizon were often absent
from the publications. For example, those models that
utilized a shorter time horizon did not account for new
biologic entries (and subsequently their biosimilars), which
may have impacted the findings.
Even when longer time horizons were used, few models
considered the impact of other possible interacting factors,
such as changes in price, practice patterns, uptake, and
access to treatments over time. Discounting was not
included in any of the three articles, and uncertainty over
future changes in price or local discounting was a stated
limitation [15, 16, 18]. Discounting and future price
changes were not included in the poster publications [22,
23, 27, 28, 30–32] except by Ruff et al. [24, 25], who
included an assumption on price erosion over the 5-year
time horizon.
3.2.4 Use of Assumptions to Populate the Model
This analysis identified a series of limitations in the data
sources used to populate the included BIAs for biosimilars.
An earlier review of budget impact models in Europe also
found that studies relied on weak sources, such as
assumptions rather than actual evidence, to populate the
models [13].
In particular, for BIAs, a paucity of robust current and
future pricing information resulted in assumptions about
biosimilar prices. These assumptions appeared to be rela-
tively arbitrary, without supporting data to provide a
rationale for the percentage discount (10–30%) applied to
the price of an originator biologic [15, 16, 27, 28, 32],
although some analyses did address uncertainty by using
several price assumptions [18, 22–24, 30]. Moreover, in
most models, there was an implicit assumption that drug
prices would remain stable over time [15, 16]. This
assumption may not have been realistic, as prices of orig-
inator biologics may fall in response to future competition
[9] and, given the availability of lower-cost alternatives,
hospitals may negotiate individual discounts from the list
price [1].
Some publications lacked clear evidence to support
uptake assumptions, such as initial market share, market
share growth, practice patterns, percentage of patients
switching from originator biologic to biosimilar, and the
percentage of new patients prescribed biosimilar treatment.
Table 4 continued
Brodszky et al. 2014 [15] Brodszky et al. 2016 [16] Jha et al. 2015 [18]
Use and cost of
other condition-
related
healthcare
services
Administration and monitoring change
included, size estimated, and value
of changea
No health outcome changea
Administration and monitoring change
included, size estimated, and value of
changea
No health outcome changea
Drug-use change included, size
estimated, and value of changea
No health outcome changea
Administration and monitoring costs
assumed to be the samea
Scenario analyses
Ranges and
alternative
values for
scenario
analyses
Partially includeda
Sensitivity analyses included using
arbitrary ranges ± 10%a
Expert opinion or published studies
not used for rangesa
Partially includeda
Sensitivity analyses included using
arbitrary ranges ± 10%a
Expert opinion or published studies not
used for rangesa
Partially includeda
Sensitivity analyses included using
arbitrary ranges ± 10%a
Expert opinion or published studies not
used for rangesa
ISPOR International Society for Pharmacoeconomics and Outcomes Research, pt(s) patient(s)
a Partially in line with ISPOR recommendations
b Fully in line with ISPOR recommendations
c Not in line with ISPOR recommendations
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For example, Brodszky et al. [15] assumed 10% annual
growth in the biologics market: 65% of patients who would
have been prescribed originator infliximab as first- or
second-line treatment would receive biosimilar infliximab
(increasing linearly to the 65% assumption by the end of
the first year and remaining unchanged to the end of the
3-year model) and 25% of patients who would have been
prescribed a non-infliximab tumor necrosis factor inhibitor
as first- or second-line treatment would receive biosimilar
infliximab (see Table 3). The authors acknowledged the
uncertainty and limitations surrounding these assumptions.
Several publications stated that the results were sensitive to
changes in pricing discount assumptions
[15, 16, 18, 24, 25, 32] and/or market uptake assumptions
[19, 24, 25, 32].
Another limitation is that authors generally did not
consider a change in future practice patterns, which could
be driven by increased utilization. Evidence from estab-
lished biosimilar markets shows expansion of biologics
usage to earlier-stage disease when biosimilars enter the
market. This expansion is likely also to occur in the USA,
although perhaps not to the same extent as in more estab-
lished markets in the near-term [9]. For example, in Eur-
ope, access has been granted to biosimilars where access to
the originator biologic was previously restricted mainly
due to cost constraints [9]. Earlier treatment intervention is
often linked to better outcomes, so effectiveness profiles
may change over time. This improvement in outcomes has
potential implications for treatment guidelines, health
system costs, and guidance provided by Health Technology
Assessment agencies, which may, in turn, further stimulate
access and increase usage. Output from BIAs could be
improved if assumptions for changes in practice patterns
and utilization were incorporated in the methodology.
4 Discussion
4.1 Potential for Improvements in Budget Impact
Modeling of Biosimilars
Currently available BIAs could be enhanced to make the
included parameters more informative to decision-makers.
Improvements include expanding the range of cost-input
estimates, more robust data inputs, inclusion of sensitivity
analyses, incorporating future market interactions, trans-
parent methods and assumptions, and more-detailed
reporting.
A wider selection of resource use and associated cost
parameters could be incorporated to make BIAs for
biosimilars more meaningful to providers and payers for
decision-making. The cost of adverse events, increased or
decreased hospitalization, office visits, and other healthcare
services, such as medication administration or monitoring,
could be included. The inclusion and exclusion of param-
eters assessed in a particular BIA require a clear rationale
in relation to the disease area and the intended audience
perspective of the BIA.
Use of more robust data sources for key parameters
would improve predictive modeling of biosimilar usage.
Real-world data on uptake, switching, and pricing are
becoming available in some markets and should be utilized
to improve the rigor and face validity of models going
forward. Where use of assumptions is unavoidable, provi-
sion of a supporting rationale and validation of the
assumptions with the relevant stakeholders are critical to
improve transparency and reduce bias. The impact of
uncertainty needs to be evaluated through sensitivity
analysis.
Other factors likely to affect biosimilar uptake, and thus
BIA assumptions, include practice setting, country, and
prescriber understanding of and experience with biosimi-
lars, which have been shown to vary with specialty. For
example, a survey conducted between November 2015 and
January 2016 of US physicians who prescribed biologics
found that, among 1201 respondents, 50–57% of oncolo-
gists compared with 44% of gastroenterologists, 38% of
dermatologists, and 35% of rheumatologists, agreed with
the statement that biosimilars would be ‘‘safe and appro-
priate for use in [treatment]-naı¨ve and existing patients’’
[33]. The evidence base for BIAs will require real-world
utilization and outcomes data to be stratified by factors
such as prescriber specialty, as well as by practice setting
and country, to improve the predictive skill of BIAs for
biosimilars.
Another consideration for BIAs (as well as for com-
prehensive value assessments) is that biologics and
biosimilar drugs are not necessarily stand-alone products.
For example, originator biologics and biosimilars may be
associated with wrap-around services provided or sup-
ported by the manufacturer, such as specialist pharmacy
services, patient access support mechanisms, and/or assis-
tance with reimbursement administration. Pharmaceutical
companies, for example, may offer a hub of support ser-
vices such as reimbursement assistance for specialty ther-
apies, patient follow-up and adherence services, and patient
assistance programs to combine insurance payments with
qualified financial assistance and co-pay programs.
Genentech and Genzyme are cited as examples of com-
panies using in-house teams, external vendors, and evolv-
ing technology platforms to provide support services to
patients with rare diseases who receive lifelong high-cost
medication necessary for disease management [34, 35].
These services may be less comprehensive for some
biosimilars and may not be available at all for intended
copies. Purchasing product from different manufacturers
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may also be associated with either more or less adminis-
trative burden than the originator biologic. Some of these
factors could be incorporated into BIAs to more broadly
reflect the costs and offsets of biosimilars.
4.2 Assessing Biosimilars Using Budge Impact
Analysis: What Questions Should Payers Ask?
BIAs should provide sufficient transparency in describing
the methodology and assumptions to be reproducible and
should be updated as more information becomes available.
Access to models that incorporate functionality for users to
produce up-to-date customized analyses that represent their
own environment and needs would provide the most utility.
In addition to ISPOR guidance, local organizations may
have their own specific recommendations for the produc-
tion of BIAs. For example, the National Pharmaceutical
Council (NPC), a US-based biopharmaceutical industry
member organization focusing on health policy research,
based on evidence, value of medicines for patients, and
innovation, has issued several recommendations on the use
of budget BIA [36, 37], including the following:
• Include all costs to and offsets in the healthcare system,
not just medication costs.
• Utilize timeframes long enough to incorporate all costs
and cost offsets associated with the disease and patient
management (e.g., some costs, such as avoided hospi-
talizations, may only become apparent in the longer
term), including lower costs of medications when
generics become available; examples could include
3 years to capture the costs of avoided hospitalizations
or 10 years in keeping with the US Congressional
Budget Office budget projections [38].
• Include realistic estimates for all necessary inputs,
incorporating information from stakeholders with
expertise.
• Conduct sensitivity analyses or report ranges around
estimated results.
Several questions might be important to help payers and
providers define the value of biosimilars and assess the
usefulness of BIAs and other economic evaluations:
• Is the totality of evidence (e.g., all available informa-
tion, including a range of structural, functional, phar-
macokinetic, pharmacodynamics, immunogenicity,
effectiveness, and safety data) for biosimilar similarity
satisfactory [39]?
• Has the BIA considered all dimensions of health
services resource use and associated costs relevant to
the decision maker, e.g., the provision of specialist
pharmacy services? Social services costs may also be
relevant in this context.
• How robust are the data sources used for the key
parameters to which the results are sensitive? If some of
the data sources are assumptions, can these assumptions
be assessed against real-world data? Do they have face
validity?
• Is the timeframe adequate to demonstrate all aspects
relevant to assessment of costs?
• Are the key drivers, assumptions, and uncertainties
(and reported ranges around estimated results) in the
analysis, as well as the way in which these may
influence interpretation and generalizability of the
results, transparent and clearly stated?
• Were BIA parameter inputs based on assumptions (e.g.,
assumptions of the number or percentage of patients
starting or switching to a biosimilar) or was the BIA
informed by actual real-world evidence?
• Are assumptions around extrapolation of indications,
use, and practice patterns for disease-specific treat-
ments realistic? In other words, can payers predict the
way in which the biosimilar will be used across disease
areas?
• If there are differences in the weight of the evidence
base between products, e.g., in the amount of evidence
provided to regulatory authorities or available from
long-term data collection through surveillance systems,
has this been taken into account in the evaluation?
• When and how often should the BIA be updated? Is it
considered a living model/analysis, including the latest
evidence?
4.3 Challenges in Defining Value for Biosimilars
Budget impact addresses questions of affordability, given a
series of model assumptions, and, on its own, does not
assess ‘value’. Since biosimilars by definition are expected
to have very similar efficacy and safety as the originator
biologic, widely used cost-effectiveness and cost-utility
analyses that incorporate health status such as in natural
clinical units and quality-adjusted life-years, respectively,
may not be well-suited to differentiate value among such
similar comparators [9, 10]. The value of biosimilars might
be better assessed using innovative value frameworks such
as multi-criteria decision analysis, which objectively and
transparently incorporate a broad range of value criteria
beyond cost that may be important to diverse stakeholders
[37, 40, 41].
For biosimilars that have demonstrated similarity to the
originator in adequately powered similarity or non-inferi-
ority studies, a cost-minimization approach would gener-
ally be appropriate, although definitions of ‘adequate
evidence’ may vary by reimbursement authority. As a cost-
minimization approach assumes equal efficacy and safety
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based on the available evidence, intended copies will not
usually have sufficient evidence of similarity compared
with the originator biologic to justify this approach.
Reimbursement authorities may require different evidence
of comparative effectiveness than that required for regu-
latory purposes, and important aspects of value for
biosimilars cannot be captured within a cost-minimization
analysis. Approved biosimilars with pharmacovigilance
programs will generate additional real-world data that may
inform value assessments.
Peripheral issues around manufacturing and mainte-
nance of an inventory over a period of time have implicit
value. Reliability of supply is important, particularly for
biologics, when considering the value of a particular pro-
duct for inclusion in a formulary. Drug shortages are an
international problem that has increased in recent years.
Inadequate supply can have multiple causal factors and far-
reaching clinical, economic, and policy implications.
Financial implications may include the additional resource
spent sourcing alternative products and the additional cost
of these alternative products, which can affect the phar-
macist, manufacturer, reimbursement authority, and/or be
passed on to the patient [42]. There is value associated with
the efficient provision of medicines to patients, which
requires the collaboration of authorization holders, manu-
facturers, wholesalers, dispensing doctors, pharmacists,
and prescribers [43, 44]. Assessing the value of such
additional services is important to stakeholders but presents
a challenge with respect to capturing related cost offsets
within the limitations of BIA or cost-minimization
methodologies.
Widening access to treatments may also be of value.
Several BIA publications state that the estimated budget
savings gained by using biosimilars instead of originator
biologics could be used to treat more patients
[15, 16, 18, 24, 25, 27], or, alternately, enable budget
reallocation for other diseases and treatment types [10].
Other types of outcomes research could capture more
complex aspects of treatment sequencing and the impact on
both costs and outcomes than BIA, but may still have
limitations. Real-world studies designed to examine the
impact and value of treating more patients who otherwise
would not receive treatment (e.g., due to access limitations)
by utilizing lower-cost biosimilars compared with origi-
nator biologics might demonstrate improved patient out-
comes and societal value. In January 2016, the National
Institute for Health and Care Excellence (NICE) in Eng-
land and Wales published revised guidance for biologics,
including biosimilars, for ankylosing spondylitis, hence
widening previously restricted access when only originator
biologics were available [45]. However, the value of this
wider access, such as improved clinical effectiveness, is
not incorporated fully in the context of BIA or cost
minimization. Possible components of the value of
biosimilars, in addition to affordability, are shown in
Fig. 1.
Furthermore, BIAs may incorporate future market
interactions, competition, and pricing effects. Stakeholders
are increasingly considering longer time horizons when
contemplating the budget impact of chronic disease ther-
apies. The Preventive Health Savings Act in the USA,
proposed in 2015, states that bodies such as the Congres-
sional Budget Office should consider longer-term impact,
up to 10 years, rather than shorter time horizons [23].
This review identified several analyses that did not
specifically fit the BIA definition but reported alternative
approaches to assessing the economic impact of biosimi-
lars. Re´muzat et al. [46–49] and others have used alterna-
tive innovative approaches to assess the budget impact of
future market developments, including the entry of
biosimilars. The authors forecast the impact of factors,
including biosimilar entry, generic entry, exclusive hospital
distribution, and national access policies, on overall phar-
maceutical expenditure. Similarly, Mulcahy et al. [50]
incorporated a more complex analysis of the biosimilar
market, including consideration of payment models, non-
price competition from originator biologics, regulatory
uncertainty, and the indirect impact of broader biologic use
on health and cost. Other reports also highlight the com-
plexity of the biosimilar market. Blackstone and Joseph
[51] emphasized the likelihood of alliances and partnering
in the biosimilar market and noted that many factors,
including safety, pricing, manufacturing, entry barriers,
physician acceptance, and marketing, may affect uptake in
the USA compared with other countries. Mestre-Ferrandiz
et al. [52] highlighted the important role of the payer in
generating incentives that encourage high-quality out-
comes data and price competition for biosimilars. Factors
such as expected price competition from originator bio-
logics and other biosimilars, and uncertain acceptance and
uptake, may reduce the incentive for companies to develop
biosimilars, which could limit competition [53].
It is important to consider the different perspectives of
the budget impact of biosimilars and identify which
stakeholders may benefit from the cost savings. Although
the BIAs included in this review primarily focused on a
national level of health service costs, it is important to
consider the savings to other stakeholders, such as patients,
private insurers, public insurers, employers, and pharmacy
benefit managers [54].
However, as acknowledged by Whitehouse et al. [28],
BIAs can only capture economic expenditures incurred
from using biosimilars; the effect on patient outcomes or
societal benefits from increased access to biologic treat-
ments needs to be addressed by further research. Future
studies are required to assess the impact that biosimilars
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may have on wider aspects of healthcare, such as earlier
access, patient outcomes, and treatment guidelines.
4.4 Study Limitations
Challenges in comparing BIA results included use of dif-
ferent units for presenting budget impact results, including
absolute cost, impact (US dollars), relative cost impact (%),
savings per year, savings per treatment, savings for total
population, savings for a hypothetical panel of 1000
patients, and savings depending on percentage price
reduction of biosimilar versus reference product. This
review also had several limitations. First, it did not include
BIAs in the public domain published in languages other
than English. We identified one BIA of an infliximab
biosimilar from Italy [21], which was not included in this
review. An English summary of this BIA is available in a
2016 ISPOR presentation by Drummond and Martin [10].
Second, as with all reviews, studies published after the
study cut-off date (30 June 2016) were not included,
namely a BIA of trastuzumab in Croatia [55]. Third, this
review did not include other types of economic analyses of
biosimilars, such as cost-utility or cost-effectiveness anal-
yses. An additional limitation was the paucity of BIAs
published as peer-reviewed articles. Nine of the 12 publi-
cations identified in this review were in poster format,
providing limited detail and impeding our ability to assess
the methodology or extent to which reproducibility for
local payer adaptation might be possible. Poster format also
limited transparency, including reporting of the purpose of
the analysis and its context, strengths, and limitations.
Without these important details, the ability to interpret the
information meaningfully from posters was limited and
therefore the data in the published articles were most
useful. It is uncertain why relatively few BIAs for mono-
clonal antibodies or fusion protein biosimilars have been
published in the peer-reviewed literature, but it may be that
the primary purpose of the BIAs is to secure reimburse-
ment or preferred formulary placement and thus dissemi-
nation as a publication may be of low priority.
5 Conclusions
This literature review has identified a paucity of peer-re-
viewed information on the budget impact of biosimilar
products. Only three full-text publications of BIAs for
biosimilar fusion proteins or monoclonal antibodies were
identified in the literature. Although these publications
generally adhered to published guidance on conductingBIAs
[12], this review identified considerable limitations in terms
of the range of included costs and reliance on assumptions
instead of robust data wheremodel inputs were reported. The
resulting estimates of budget impact were sensitive to these
assumptions and these shortcomings highlight the need for
additional information in the public domain regarding BIAs
for biosimilars of monoclonal antibodies and fusion proteins
as these products increasingly become available. The limi-
tations of BIA for assessing pharmaceutical products in
general have previously been reported [13]. Better BIA
reporting would do much to improve the utility and repro-
ducibility of these models, either through provision of more
comprehensive information within the publication or of
supplementary materials or links to additional content in
posters, where space is at a premium.
Published guidance distinguishes BIAs as a tool pri-
marily for assessing affordability, while other frameworks
are designed to assess value [37]. The ISPOR guidelines
state that the intended use of a BIA includes addressing the
expected changes in healthcare system expenditures after
the adoption of a new intervention, as well as budgeting or
resource planning [12]. Thus, although well-conducted
Added value
considerations
Expanded access to treatment Supply chain benefits Wrap-around services 
• More patients treated 
  with biologics
• Patients treated with
  biologic drugs sooner
• Reduced administrative
  burden
• Manufacturing consistency
• Inventory maintenance
• Supply reliability
• Specialist pharmacy services
• Patient access support
  mechanisms
• Assistance with reimbursement
  administration
Fig. 1 Additional value considerations of biosimilars beyond budget impact
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BIAs, in line with published guidance, form an important
part of affordability evaluation, other complementary
assessments are required to demonstrate the value of
biosimilars.
Further research and novel approaches for assessing the
incremental value of biosimilars are warranted, including
incorporating more aspects of value than simply the dif-
ference in future spending on biosimilar products com-
pared with biologics. Although several BIAs in this review
evaluated the role of budget savings from less expensive
biosimilars and expanding patient access to biologics in
general, it is clear that BIAs on their own are inadequate to
fully evaluate the economic impact of changes in treatment
patterns, pricing, and market dynamics [46, 53].
Also of note, most clinical and payer experience with
biosimilars stems from European countries that have a
single-payer mechanism. In the USA, the implications of
biosimilar utilization can be expected to differ as the
market is categorized by multiple payers and greater flu-
idity, both in terms of formulary structure and patients’
choice of different health plans.
Although biosimilar uptake outside of the USA can
provide some insight, the unique nature of the US market
undoubtedly will result in different interpretations of the
value of biosimilars. BIAs are one tool of many for
assessing the impact of biosimilars on healthcare costs and
quality. However, the paucity of published data on the
budget impact of biosimilars limits interpretation, and
additional economic models of biosimilars are needed to
assess the range of their potential budget impact on the US
healthcare system.
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